{"status": "Ok", "redirect_url": "https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnsons-RYBREVANT-FASPRO-amivantamab-and-hyaluronidase-lpuj-receives-U-S--FDA-Priority-Review-as-potential-first-in-class-EGFR--and-MET-targeted-subcutaneous-treatment-for-advanced-head-and-neck-cancer/default.aspx", "message": "News view counter 858089 successfully enlarged"}